Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bupropion: risks and benefits.

Sarah Ross1, David Williams

  • 1Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, AB24 2ZD, UK.

Expert Opinion on Drug Safety
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural repair by NT3-chitosan via enhancement of endogenous neurogenesis after adult focal aspiration brain injury.

Biomaterials·2017
Same author

<i>Pseudomonas aeruginosa</i> adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.

The European respiratory journal·2017
Same author

Engagement of the medical-technology sector with society.

Science translational medicine·2017
Same author

A Nomogram for Calculation of Maximum Recommended Dose by Volume of Local Anesthetic in Pediatric Dentistry.

Pediatric dentistry·2017
Same author

Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist.

Abdominal radiology (New York)·2017
Same author

Chronic Granulomatous Disease Presenting as Aspergillus Fumigatus Pneumonia in a Previously Healthy Young Woman.

The American journal of case reports·2017
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Bupropion is an effective smoking cessation aid, recommended by major guidelines. While its exact mechanism is unknown, it is considered cost-effective for helping people quit smoking.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Public Health

Background:

  • Cigarette smoking is a leading preventable cause of death globally.
  • Smoking cessation success rates are low, with high relapse rates, indicating a need for effective therapies.

Purpose of the Study:

  • To review the efficacy and safety of bupropion as a smoking cessation therapy.
  • To discuss the potential mechanism of action and cost-effectiveness of bupropion.

Main Methods:

  • Literature review of bupropion's use in smoking cessation.
  • Analysis of clinical guidelines and research on bupropion's effectiveness.
  • Examination of bupropion's safety profile, including seizure risk.

Main Results:

Related Experiment Videos

  • Bupropion is recommended as a first-line smoking cessation treatment in US and UK guidelines.
  • The precise mechanism of bupropion in smoking cessation is not fully understood but may involve dopaminergic pathways.
  • Bupropion is associated with a risk of seizures, requiring careful patient selection and monitoring.
  • Bupropion has demonstrated cost-effectiveness as a smoking cessation therapy.

Conclusions:

  • Bupropion is an effective and recommended pharmacotherapy for smoking cessation.
  • Further research into bupropion's mechanism of action is warranted.
  • Bupropion offers a cost-effective option for smoking cessation programs, despite potential risks.